Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed Apr 16, 2010
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2010-04-14$7.00/sh−1,309$9,163→ 882,445 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.